Tag: 100-200

On February 28, 1986, Hu, Yaofei; Hu, Hongwen published an article.Product Details of 109486-06-8 The title of the article was Synthesis of multidentate ligands. (II). Synthesis of bis-Schiff bases from 5-R-2-methoxyisophthalaldehydes. And the article contained the following:

Title Schiff bases I (R = Me, Ph, MeO, Cl, Br) were prepared I were demethylated by refluxing the complexes of I and Cu(OAc)2 in dilute HCl. The experimental process involved the reaction of 2,5-Dihydroxyisophthalaldehyde(cas: 109486-06-8).Product Details of 109486-06-8

The Article related to methoxyphthaladehyde schiff base aminophenol, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Phenols, Thiophenols, and Derivatives Including Phenol and Thiophenol Ethers and Esters and other aspects.Product Details of 109486-06-8

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On May 27, 2020, Han, Bin; Li, Yao; Ji, Xuan; Song, Xianneng; Ding, Shuaishuai; Li, Baili; Khalid, Hira; Zhang, Yaogang; Xu, Xiaona; Tian, Lixian; Dong, Huanli; Yu, Xi; Hu, Wenping published an article.Name: 1-Decanethiol The title of the article was Systematic Modulation of Charge Transport in Molecular Devices through Facile Control of Molecule-Electrode Coupling Using a Double Self-Assembled Monolayer Nanowire Junction. And the article contained the following:

We report a novel solid-state mol. device structure based on double self-assembled monolayers (D-SAM) incorporated into the suspended nanowire architecture to form a “Au|SAM-1||SAM-2|Au” junction. Using com. available thiol mols. that are devoid of synthetic difficulty, we constructed a “Au|S-(CH2)6-ferrocene||SAM-2|Au” junction with various lengths and chem. structures of SAM-2 to tune the coupling between the ferrocene conductive MO and electrode of the junction. Combining low noise and a wide temperature range measurement, we demonstrated systematically modulated conduction depending on the length and chem. nature of SAM-2. Meanwhile, the transport mechanism transition from tunneling to hopping and the intermediate state accompanied by the current fluctuation due to the coexistence of the hopping and tunneling transport channels were observed Considering the versatility of this solid-state D-SAM in modulating the electrode-mol. interface and electroactive groups, this strategy thus provides a novel facile strategy for tailorable nanoscale charge transport studies and functional mol. devices. The experimental process involved the reaction of 1-Decanethiol(cas: 143-10-2).Name: 1-Decanethiol

The Article related to self assembly monolayer nanowire gold thiol electron transfer, Electric Phenomena: Conduction and Conductivity, Semiconductivity, Resistance, Current Carriers, Galvanomagnetic and Acoustoelectric Effects and other aspects.Name: 1-Decanethiol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On June 21, 2007, Vanotti, Ermes; Forte, Barbara; Martina, Katia; Menichincheri, Maria; Cirla, Alessandra; Orsini, Paolo published a patent.HPLC of Formula: 87674-15-5 The title of the patent was Preparation of heteroarylpyrrolopyridinones active as kinase inhibitors. And the patent contained the following:

The title compounds I [A = pyridin-4-yl, 3-fluoropyridin-4-yl, 2-aminopyrimidin-4-yl; R1 = H, halo, alkyl; R2 = H, alkyl, cycloalkyl, etc.; R3-R6 = H, haloalkyl, polyfluorinated alkyl, etc.; and their pharmaceutically acceptable salts] that are effective in antagonizing activity toward Cdk2 or Cdc7, were prepared Over twenty compounds I were prepared Thus, reacting tert-Bu DL-6-(3-aminopropyl)-4-oxo-2-(pyridin-4-yl)-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylate with 2-methylpropionaldehyde in the presence of sodium cyanoborohydride followed by deprotection afforded DL-6-(3-isobutylaminopropyl)-2-(pyridin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one as dihydrochloride. The experimental process involved the reaction of 1-(3-Fluoropyridin-4-yl)ethanol(cas: 87674-15-5).HPLC of Formula: 87674-15-5

The Article related to heteroarylpyrrolopyridinone preparation cdk2 cdc7 protein kinase inhibitor, heteroaryl pyrrolopyridinone preparation cdk2 cdc7 protein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.HPLC of Formula: 87674-15-5

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On June 30, 2020, Sahoo, Apurba Ranjan; Lalitha, Gummidi; Murugesh, V.; Bruneau, Christian; Sharma, Gangavaram V. M.; Suresh, Surisetti; Achard, Mathieu published an article.HPLC of Formula: 111-29-5 The title of the article was Direct Access to (±)-10-Desbromoarborescidine A from Tryptamine and Pentane-1,5-diol. And the article contained the following:

A single step synthetic strategy for (±)10-desbromoarborescidine A is described. Starting from tryptamine and pentane-1,5-diol, this acceptorless dehydrogenative condensation process is efficiently catalyzed by a ruthenium complex featuring proton-responsive phosphine-pyridone ligand. The experimental process involved the reaction of Pentane-1,5-diol(cas: 111-29-5).HPLC of Formula: 111-29-5

The Article related to desbromoarborescidine a preparation, tryptamine pentanediol dehydrogenative condensation ruthenium complex phosphine pyridone catalyst, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.HPLC of Formula: 111-29-5

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Zhu, Lei published a patent.Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted (azabicycloalkyl)indoles and (azabicycloalkyl)pyridoindoles as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; each R2 independently = H, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; R3 = H, halo, (un)substituted aryl, heteroaryl, etc.; A = (CH2)n; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR9, C(R9)2, N, or NR9; Y = CR9, C, or N; Z = CH, C, or N; R9 = H, halo, NH2 and derivatives, (un)substituted alkyl etc.; m = 0 to 3, n = 1 or 2; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·HCl was prepared by methylation of 3-bromophenylhydrazine hydrochloride with Me iodide followed by heterocyclization with 1-azabicyclo[3,2,1]octan-4-one, amination with 4-(benzyloxy)pyridin-2(1H)-one, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·HCl demonstrated a Ki value of 6.4 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azinone azabicycloalkyl indole preparation mch1 receptor antagonist treatment disease, azabicycloalkyl pyridoindole preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Henderson, Alan John; Hadden, Mark; Freeman, Emily Elizabeth published a patent.Product Details of 386704-04-7 The title of the patent was Preparation of (azabicycloalkyl)indole and (azabicycloalkyl)pyrrolopyridine derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; D = NR2; R2 = H, (un)substituted alkyl, alkynyl, aryl, etc.; each R3 independently = H, halo, NH2 and derivatives, (un)substituted heteroaryl, etc; R4 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc; A = (CH)n; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR10, C(R10)2, N, or NR10; Y = CR10, C, or N; Z = CH, C, or N; R10 = H, halo, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; m = 0 to 3; n = 1 or 2; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-2-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 3-bromo-5-methyl-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 6.5 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Product Details of 386704-04-7

The Article related to azabicycloalkane indole derivative preparation mch1 receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Grabowski, James Francis, Jr.; Freeman, Emily Elizabeth published a patent.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted azepinoindole derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [A = CH, C, or N; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR18, C(R18)2, N, or NR18; Y = CR18, C, or N; Z = CH, C, or N; R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; R2 – R5 and R9 – R12 independently = H, halo, NH2 and derivatives, NHCO2H and derivatives, etc.; each R6 independently = H, halo, OH and derivatives, NH2 and derivatives, etc.; R7 = H, halo, NHCO2H and derivatives, (un)substituted aryl, heteroaryl, etc.; R8 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc.; R13 and R14 independently = H, alkyl, haloalkyl, cycloalkyl, etc.; R18 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; G = NR8CR9R10CR11R12, CR9R10NR8CR11R12, or CR9R10CR11R12NR8; provided that when G = CR9R10NR8CR11R12, R2 and R3 are not CONR13R14; n = 0 to 3; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-5-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 8-bromo-6-methyl-1,2,4,5-tetrahydroazepino[4,5-b]indole-3(6H)-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 10.1 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azinone azepinoindole derivative preparation mch receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On December 12, 1996, Hulin, Bernard; Hoover, Dennis J.; Treadway, Judith L.; Martin, William H. published a patent.Recommanded Product: 62640-03-3 The title of the patent was Preparation of substituted indole-2-carboxamides and derivatives as glycogen phosphorylase inhibitors.. And the patent contained the following:

Title compounds [I; dotted line = optional double bond; A = CH, CR20, CH2, CHR21; ; R20 = alkyl, halo; R21 = alkyl; R1, R10, R11 = H, halo, NO2, cyano, alkyl, alkoxy, CH2F, CHF2, CF3; R2 = H, R3 = H, alkyl; R4 = H, Me, Et, Pr, hydroxyalkyl, alkoxyalkyl, (substituted) phenylalkyl, phenylhydroxyalkyl, thienylalkyl, furylalkyl, pyridylalkyl, thiazolylalkyl, triazinylalkyl, etc.; R5 = H, OH, F, alkyl, alkoxy, alkanoyl, amionoalkoxy, carboxyalkoxy, etc.; R6 = CO2H, alkoxycarbonyl, CONR8R9, COR12; R8 = H, alkyl, OH, alkoxy; R9 = H, (substituted) alkyl, OH, alkoxy, methylene-perfluorinated alkyl, Ph, pyridyl, thienyl, furyl pyrrolyl, pyrrolidinyl, oxazolyl, thiazolyl, pyranyl, piperidinyl, morpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc.; R12 = piperazin-1-yl, 4-alkylpiperazin-1-yl, thiomorpholino, substituted oxazetidin-2-yl, etc.], were prepared as glycogen phosphorylase inhibitors (no data). Thus, iso-Pr (3S)-amino-4-phenyl-(2R)-hydroxybutyrate, 5-chloroindole-2-carboxylic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and 1-hydroxybenzotriazole were stirred 18 h in CH2Cl2 to give 91% iso-Pr (3S)-[(5-chloro-1H-indole-2-carbonyl)amino]-(2R)-hydroxy-4-phenylbutyrate. The experimental process involved the reaction of 2-(Methylamino)ethan-1-ol hydrochloride(cas: 62640-03-3).Recommanded Product: 62640-03-3

The Article related to indolecarboxamide substituted preparation glycogen phosphorylase inhibitor, cardiovascular agent indolecarboxamide substituted, diabetes treatment indolecarboxamide substituted and other aspects.Recommanded Product: 62640-03-3

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Brandhofer, Tobias; Stinglhamer, Martin; Derdau, Volker; Mendez, Maria; Poverlein, Christoph; Garcia Mancheno, Olga published an article in 2021, the title of the article was Easy access to drug building-blocks through benzylic C-H functionalization of phenolic ethers by photoredox catalysis.Category: alcohols-buliding-blocks And the article contains the following content:

A visible light-mediated photocatalyzed C-C-bond forming method for the benzylic C-H functionalization of phenolether containing synthetic building blocks based on a radical-cation/deprotonation strategy is reported. This method allows the mild, selective generation of benzyl radicals in phenolic complex mols. and drug-like compounds, providing new entries in synthetic and medicinal chem. The experimental process involved the reaction of H-Phg(4-OH)-OH(cas: 32462-30-9).Category: alcohols-buliding-blocks

The Article related to tyrosine methyl ester functionalization alkylation methyl acrylate photoredox catalysis, peptide synthesis alkylation photoredox catalysis reaction mechanism cyclic voltammetry and other aspects.Category: alcohols-buliding-blocks

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Yang, Wu; Li, Yingzi; Zhu, Jiefeng; Liu, Wentan; Ke, Jie; He, Chuan published an article in 2020, the title of the article was Lewis acid-assisted Ir(III) reductive elimination enables construction of seven-membered-ring sulfoxides.HPLC of Formula: 72364-46-6 And the article contains the following content:

Iridium has played an important role in the evolution of C-H activation chem. over the last half century owing to its high reactivity towards stoichiometric C-H bond cleavage; however, the use of Ir(III) complexes in catalytic C-H functionalization/C-C bond formation appears to have fallen off significantly. The main problem lies in the reductive elimination step, as iridium has a tendency to form stable and catalytically inactive Ir(III) species. Herein, with a rationally designed Lewis acid assisted oxidatively induced strategy, the sluggish Ir(III) reductive elimination is successfully facilitated, enabling the facile C-C bond formation. The X-ray crystal structure of a silver salt adduct of iridacycle and DFT calculations demonstrate that the sulfoxide group acts as a key bridge connecting the Ir(III) metal center with the silver Lewis acid, which facilitates the reductive elimination of the Ir(III) metallacycle. Further identification of oxidants was carried out by performing stoichiometric reactions, which enables the development of catalytic construction of various highly functionalized seven-membered-ring sulfoxides e.g., 5,7-dihydrodibenzo[c,e]thiepine 6-oxide, that are of great interest in medicinal chem. and materials science. The experimental process involved the reaction of (2-Fluorophenyl)methanethiol(cas: 72364-46-6).HPLC of Formula: 72364-46-6

The Article related to dihydrodibenzothiepine oxide preparation chemoselective regioselective density functional theory, aralkyl sulfoxide oxidative reductive elimination lewis acid iridium catalyst and other aspects.HPLC of Formula: 72364-46-6

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts